![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MTFMT |
Gene summary for MTFMT |
![]() |
Gene information | Species | Human | Gene symbol | MTFMT | Gene ID | 123263 |
Gene name | mitochondrial methionyl-tRNA formyltransferase | |
Gene Alias | COXPD15 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96DP5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
123263 | MTFMT | S014 | Human | Liver | HCC | 6.14e-03 | 2.16e-01 | 0.2254 |
123263 | MTFMT | S015 | Human | Liver | HCC | 3.24e-08 | 4.36e-01 | 0.2375 |
123263 | MTFMT | S016 | Human | Liver | HCC | 1.10e-09 | 3.43e-01 | 0.2243 |
123263 | MTFMT | S027 | Human | Liver | HCC | 3.97e-05 | 4.47e-01 | 0.2446 |
123263 | MTFMT | S028 | Human | Liver | HCC | 3.89e-19 | 6.66e-01 | 0.2503 |
123263 | MTFMT | S029 | Human | Liver | HCC | 3.82e-22 | 7.62e-01 | 0.2581 |
123263 | MTFMT | C04 | Human | Oral cavity | OSCC | 8.64e-11 | 5.52e-01 | 0.2633 |
123263 | MTFMT | C21 | Human | Oral cavity | OSCC | 3.24e-23 | 7.25e-01 | 0.2678 |
123263 | MTFMT | C30 | Human | Oral cavity | OSCC | 5.99e-06 | 3.94e-01 | 0.3055 |
123263 | MTFMT | C43 | Human | Oral cavity | OSCC | 2.23e-06 | 1.62e-01 | 0.1704 |
123263 | MTFMT | C46 | Human | Oral cavity | OSCC | 3.92e-03 | 1.90e-01 | 0.1673 |
123263 | MTFMT | C08 | Human | Oral cavity | OSCC | 2.69e-08 | 2.31e-01 | 0.1919 |
123263 | MTFMT | LN46 | Human | Oral cavity | OSCC | 6.56e-03 | 2.47e-01 | 0.1666 |
123263 | MTFMT | SYSMH1 | Human | Oral cavity | OSCC | 1.93e-03 | 9.00e-02 | 0.1127 |
123263 | MTFMT | SYSMH2 | Human | Oral cavity | OSCC | 1.05e-07 | 2.67e-01 | 0.2326 |
123263 | MTFMT | SYSMH3 | Human | Oral cavity | OSCC | 7.61e-07 | 2.08e-01 | 0.2442 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:000641322 | Liver | HCC | translational initiation | 94/7958 | 118/18723 | 1.39e-16 | 1.24e-14 | 94 |
GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
GO:0009451 | Liver | HCC | RNA modification | 101/7958 | 167/18723 | 2.02e-06 | 2.78e-05 | 101 |
GO:0006400 | Liver | HCC | tRNA modification | 60/7958 | 90/18723 | 3.09e-06 | 4.09e-05 | 60 |
GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
GO:000641318 | Oral cavity | OSCC | translational initiation | 96/7305 | 118/18723 | 4.02e-21 | 7.06e-19 | 96 |
GO:00080332 | Oral cavity | OSCC | tRNA processing | 78/7305 | 127/18723 | 2.56e-07 | 4.00e-06 | 78 |
GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
GO:00094511 | Oral cavity | OSCC | RNA modification | 95/7305 | 167/18723 | 2.05e-06 | 2.62e-05 | 95 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa006702 | Liver | HCC | One carbon pool by folate | 17/4020 | 20/8465 | 6.04e-04 | 2.50e-03 | 1.39e-03 | 17 |
hsa0067011 | Liver | HCC | One carbon pool by folate | 17/4020 | 20/8465 | 6.04e-04 | 2.50e-03 | 1.39e-03 | 17 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MTFMT | SNV | Missense_Mutation | rs758882234 | c.839N>T | p.Ala280Val | p.A280V | Q96DP5 | protein_coding | deleterious(0.05) | benign(0.076) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MTFMT | SNV | Missense_Mutation | c.998N>T | p.Ser333Leu | p.S333L | Q96DP5 | protein_coding | deleterious(0.04) | possibly_damaging(0.578) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MTFMT | SNV | Missense_Mutation | c.1015N>A | p.Ser339Thr | p.S339T | Q96DP5 | protein_coding | tolerated(0.32) | benign(0) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
MTFMT | SNV | Missense_Mutation | c.1011N>T | p.Lys337Asn | p.K337N | Q96DP5 | protein_coding | deleterious(0.04) | possibly_damaging(0.865) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MTFMT | SNV | Missense_Mutation | novel | c.1030N>A | p.Asp344Asn | p.D344N | Q96DP5 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MTFMT | SNV | Missense_Mutation | novel | c.467C>T | p.Pro156Leu | p.P156L | Q96DP5 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
MTFMT | SNV | Missense_Mutation | novel | c.541N>G | p.Arg181Gly | p.R181G | Q96DP5 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MTFMT | SNV | Missense_Mutation | novel | c.992N>G | p.Val331Gly | p.V331G | Q96DP5 | protein_coding | deleterious(0) | possibly_damaging(0.7) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MTFMT | SNV | Missense_Mutation | novel | c.573N>C | p.Glu191Asp | p.E191D | Q96DP5 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MTFMT | SNV | Missense_Mutation | novel | c.949N>G | p.Ser317Ala | p.S317A | Q96DP5 | protein_coding | deleterious(0.03) | benign(0.171) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |